The Jazz Pharmaceuticals plc – (JAZZ) Lifted to “Buy” at Zacks Investment Research

The Jazz Pharmaceuticals plc – (JAZZ) Lifted to “Buy” at Zacks Investment Research

According to Zacks, “Jazz’s missed estimates for earnings and sales in the first quarter of 2017. The company’s sleep disorder drug, Xyrem, is the only FDA-approved product for both cataplexy and EDS. However, Xyrem is facing patent challenges. Jazz has also been facing challenges in building sufficient inventory levels for leukemia drug Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions this year. However, its lead pipeline candidate, JZP-110, being developed for the treatment of EDS in patients suffering from narcolepsy and OSA, complements its existing sleep disorder portfolio. In Oct 2016, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos, which was completed in early Apr 2017. Jazz’ shares outperformed the industry so far this year.”

Zacks Investment Research upgraded shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) from a hold rating to a buy rating in a report released on Monday, May 15th. Zacks Investment Research currently has $174.00 target price on the specialty pharmaceutical company’s stock.

Several other research analysts have also issued reports on the stock. Janney Montgomery Scott upgraded shares of Jazz Pharmaceuticals plc – from a neutral rating to a buy rating and increased their price target for the stock from $138.00 to $175.00 in a research note on Thursday, April 6th. Vetr lowered shares of Jazz Pharmaceuticals plc – from a strong-buy rating to a buy rating and set a $161.19 price target for the company. in a research note on Monday, March 27th. BMO Capital Markets reiterated a top pick rating and issued a $192.00 price target on shares of Jazz Pharmaceuticals plc – in a research note on Wednesday, February 15th. Deutsche Bank AG set a $176.00 price target on shares of Jazz Pharmaceuticals plc – and gave the stock a buy rating in a research note on Thursday, April 6th. Finally, Cantor Fitzgerald reiterated a buy rating on shares of Jazz Pharmaceuticals plc – in a research note on Thursday, April 27th. Three investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $182.30. Jazz Pharmaceuticals plc – (NASDAQ JAZZ) opened at 148.59 on Monday. Jazz Pharmaceuticals plc – has a one year low of $95.80 and a one year high of $163.75. The firm has a market capitalization of $8.92 billion, a PE ratio of 22.45 and a beta of 1.22. The stock’s 50 day moving average is $153.80 and its 200-day moving average is $131.85.

In related news, EVP Suzanne Sawochka Hooper sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $160.00, for a total value of $400,000.00. Following the transaction, the executive vice president now owns 39,649 shares of the company’s stock, valued at $6,343,840. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 11th. The stock was sold at an average price of $152.12, for a total transaction of $152,120.00. Following the completion of the transaction, the chief executive officer now directly owns 308,491 shares in the company, valued at approximately $46,927,650.92. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 54,333 shares of company stock worth $8,343,272. Insiders own 3.90% of the company’s stock. Institutional investors have recently bought and sold shares of the company. Envestnet Asset Management Inc. increased its position in Jazz Pharmaceuticals plc – by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 295 shares during the last quarter. World Asset Management Inc acquired a new position in Jazz Pharmaceuticals plc – during the first quarter worth about $205,000. Bridges Investment Management Inc. acquired a new position in Jazz Pharmaceuticals plc – during the first quarter worth about $208,000. Private Advisor Group LLC acquired a new position in Jazz Pharmaceuticals plc – during the first quarter worth about $215,000. Finally, Mn Services Vermogensbeheer B.V. increased its position in Jazz Pharmaceuticals plc – by 2.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,601 shares of the specialty pharmaceutical company’s stock worth $217,000 after buying an additional 44 shares during the last quarter. 88.56% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals plc – Company Profile Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:JAZZ”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on Jazz Pharmaceuticals plc – (JAZZ) For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment